Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.
Anavex’s newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX®2-73 (blarcamesine) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback